Drug intelligence / Profile preview

hTERT324-332 peptide

Development stage: Unknown
Lead developer: Ehime University
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

hTERT324-332 peptide is a peptide vaccine designed to induce an immune response against human telomerase reverse transcriptase (hTERT). It functions by stimulating hTERT324–332-specific CD8+ cytotoxic T lymphocytes (CTLs) in the peripheral blood, aiming to target cancer cells that express hTERT. The peptide is administered via subcutaneous injection, typically with an adjuvant like Montanide ISA51. It has been investigated in phase I/II clinical studies for the treatment of metastatic renal cell carcinoma and metastatic prostate cancer.

Other names: VYAETKHFL

Targets

TCR (T cell antigen receptor complex)HLA-A*24:02/hTERT324-332 (Human leukocyte antigen A*24:02 presenting human telomerase reverse transcriptase 324-332 epitope)

Beyond the preview

Go deeper on hTERT324-332 peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hTERT324-332 peptide.

Explore the full profile